Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Author:

Castellino Sharon M.1ORCID,Giulino‐Roth Lisa2,Harker‐Murray Paul3,Kahn Justine M.4ORCID,Forlenza Christopher5,Cho Steve6,Hoppe Bradford7ORCID,Parsons Susan K.8,Kelly Kara M.9,

Affiliation:

1. Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta/Department of Pediatrics Emory University School of Medicine Atlanta Georgia USA

2. Department of Pediatrics Weill Cornell Medical College New York New York USA

3. Pediatric Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

4. Division of Pediatric Hematology Oncology and Stem Cell Transplantation Columbia University Medical Center New York New York USA

5. Department of Pediatrics Memorial Sloan‐Kettering Cancer Center New York New York USA

6. Department of Radiology University of Wisconsin/University of Wisconsin Carbone Comprehensive Cancer Center Madison Wisconsin USA

7. Department of Radiation Oncology Mayo Clinic Jacksonville Florida USA

8. Department of Medicine Tufts University School of Medicine/Department of Pediatrics Reid R. Sacco AYA Cancer Program/Division of Hematology/Oncology Tufts University School of Medicine/Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston Massachusetts USA

9. Department of Pediatric Oncology Roswell Park Comprehensive Cancer Center/Department of Pediatrics University at Buffalo Jacobs School of Medicine and Biomedical Sciences Buffalo New York USA

Abstract

AbstractThe goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials include: (i) superior event‐free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high‐risk disease, (ii) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and (ii) the potential to select a population that can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead a National cancer Institute National Clinical Trials Network phase 3 trial to evaluate the combination of Bv/nivolumab in early‐stage disease. Ongoing advances in technology and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.

Funder

St. Baldrick's Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference76 articles.

1. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study

2. U.S. Cancer Statistics Working Group.U.S. Cancer Statistics Data Visualizations Tool based on 2021 submission data (1999–2019): U.S.Department of Health and Human Services Centers for Disease Control and Prevention and National Cancer Institute;June2022. Accessed May 30 2023.https://gis.cdc.gov/Cancer/USCS/#/Demographics/

3. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3